We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Proteomic Profiling Enables Earlier Diagnosis of Pancreatic Cancer

By LabMedica International staff writers
Posted on 02 Apr 2014
A newly developed method has correctly identified pancreatic cancer potential with higher accuracy than cytology and cyst fluid carcinoembryonic antigen (CEA) testing, and could be used to improve prevention and reduce unwarranted surgery.

Current prognosis for pancreatic cancer (PCa) is such that only about 5% of patients survive 5 years after diagnosis. More...
Pancreatic cystic lesions (PCLs) almost invariably reflect an underlying inflammatory or neoplastic condition, ranking among the most important incidentalomas to have emerged with radiological advances. This offers an opportunity for preventive intervention against pancreatic cancer (ductal adenocarcinoma) because a substantial proportion of cystic tumors can be considered precursor lesions – of malignant potential (premalignant or malignant tumors). Although PCLs (found in 10% of the population above age 70 years, and common also in younger people) can now be discovered with CT or MRI, imaging alone cannot determine which cysts are at risk for developing into cancer. It often becomes necessary to puncture the cyst and test for tumor markers in the fluid; however these analyses are not reliable. Removing the cyst by surgery, knowing that it may turn out to be benign is also problematic, since the operation is extensive with considerable risks for the patient.

Much better diagnostic tools are required for patients to benefit from PCL detection. Researchers at The Sahlgrenska Academy (Gothenburg, Sweden) have now developed a mass spectrometry (MS) based method that identified PCa precursor cysts with 97% certainty (of 79 examined cysts). The method detects the presence of mucus protein, mucins, in the cystic fluid. The PCL proteomic mucin profiling accuracy was nearly identical (96.6% vs. 98.0%) between the discovery (n = 29) and validation (n = 50) cohorts. “This is an exceptionally good result for a diagnostic test, and we are very hopeful that the method will enable more instances of early discovery of pancreatic cancer, at a stage when the cancer can be treated or prevented,” said Dr. Karolina Jabbar, PhD student at The Sahlgrenska Academy and physician at The Sahlgrenska University Hospital.

The method was also tested in a blinded analysis of existing tumors and determined with about 90% certainty which tumors have already developed into cancers. Therefore, the method could also be used to determine which patients require immediate surgery and which can wait while under continued monitoring.

Professor Gunnar C. Hansson, who initiated the study with senior physician and assistant professor Riadh Sadik, is convinced that MS-based proteomics will soon be introduced in health care: “The technique has been developed, and we can now measure biomarkers both quickly and exactly. Moreover, the method requires minimal biomaterial, in this case 25 times less cyst fluid than conventional tumor marker analyses. I am certain that within 5 years the mass spectrometers will have moved into the hospital corridors”, he said.

Jabber et al. describe the method in the Journal of the National Cancer Institute, February, 2014.

Related Links:

The Sahlgrenska Academy



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.